CJC-1295 5mg is a synthetic tetrasubstituted 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH) designed to extend plasma half-life and stimulate anterior pituitary somatotrophs. Researched extensively in preclinical models for its ability to elevate endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1), it serves as an essential tool for investigating tissue repair, nitrogen retention, and endocrine signaling pathways.
CJC-1295 5mg is a synthetic tetrasubstituted 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH) designed to extend plasma half-life and stimulate anterior pituitary somatotrophs. Researched extensively in preclinical models for its ability to elevate endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1), it serves as an essential tool for investigating tissue repair, nitrogen retention, and endocrine signaling pathways.
CJC-1295 is a modified, truncated synthetic peptide derived from the naturally occurring 44-amino-acid structure of endogenous GHRH. Specifically, CJC-1295 represents a modified version of the bioactive sequence known as GRF 1-29. To prevent rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) in extracellular matrices, four strategic amino acid substitutions are introduced at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These precise modifications significantly enhance peptide stability without reducing its affinity for the GHRH receptor (GHRH-R).
In analytical laboratory applications, a cjc 1295 5mg vial typically contains a lyophilized cake formulated for reconstitution in physiological or aqueous diluents. When evaluating this compound in vitro or in vivo animal models, researchers investigate how structural stabilization alters metabolic clearance compared to native GHRH. The molecular formula of non-conjugated modified GRF 1-29 is C152H252N44O42 with a molecular mass of approximately 3367.9 Da. Understanding these molecular parameters is critical when calculating molar concentrations for cell culture exposure or mass spectrometry validation.
The primary biochemical mechanism of CJC-1295 involves high-affinity binding to the GHRH receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on the cell membranes of somatotroph cells in the anterior pituitary gland. Upon ligand binding, the receptor undergoes a conformational change that activates the heterotrimeric Gs alpha subunit. This subunit stimulates membrane-bound adenylyl cyclase, initiating the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP).
The resulting rise in intracellular cAMP activates protein kinase A (PKA), which subsequently phosphorylates specific transcription factors, including cAMP response element-binding protein (CREB). This signaling cascade drives the transcription of the growth hormone gene and triggers the exocytosis of pre-stored GH vesicles into systemic circulation. In preclinical models, sustained activation of this pathway by growth hormone-releasing hormone analogs leads to a proportional increase in hepatic production of insulin-like growth factor 1 (IGF-1), establishing a reliable axis for examining tissue turnover, protein synthesis, and cellular regeneration.
Preclinical studies evaluating CJC-1295 demonstrate a marked prolongation of growth hormone release compared to wild-type GHRH. In rodent models, single-dose administrations of stabilized GHRH variants produce sustained elevations of circulating GH and IGF-1 levels without disrupting the normal pulsatile release pattern of pituitary somatotrophs. This distinction is vital for researchers studying physiological endocrine responses, as continuous non-pulsatile exposure can lead to receptor desensitization or downregulation.
Furthermore, expanded investigations in rodent models indicate that elevated IGF-1 concentrations secondary to GHRH analog exposure correlate with augmented cellular repair mechanisms. Researchers tracking biomarkers of collagen synthesis, myoblast proliferation, and osteoblast differentiation observe increased metabolic activity in targeted tissues. These data suggest that CJC-1295 provides a predictable, controlled experimental substrate for mapping the down-stream physiological impacts of somatotropic stimulation in preclinical research database protocols.
A critical distinction in secretagogue research lies between CJC-1295 without DAC (frequently referred to as Modified GRF 1-29) and CJC-1295 with Drug Affinity Complex (DAC). The inclusion of the DAC moiety—a bioconjugate reactive group (maleimidopropionic acid)—allows the peptide to covalently bind to circulating serum albumin upon administration. This albumin-binding mechanism extends the elimination half-life from approximately 30 minutes (Mod GRF 1-29) to up to 6–8 days in mammalian test subjects.
Choosing between these formulations depends entirely on the design of the research trial. Studies aimed at mimicking acute, physiological GH pulses typically utilize Mod GRF 1-29 (CJC-1295 without DAC). Conversely, protocols designed to evaluate continuous, basal IGF-1 elevation over extended timeframes leverage CJC-1295 with DAC. Both variants remain key focal points in contemporary studies examining neuroendocrine regulation, cellular senolysis, and body composition alteration in rodent paradigms.
To fully map the somatotropic pathway, researchers often compare GHRH analogs against growth hormone secretagogue receptor (GHSR) agonists. While GHRH analogs act via the GHRH-R pathway, GHSR agonists operate through the ghrelin receptor to trigger complementary GH release. Evaluating these classes in tandem allows investigators to measure potential synergistic effects on somatotroph depolarization.
Within this research domain, CJC-1295 is frequently evaluated alongside alternative peptides in the same functional family. For instance, pairing CJC-1295 with ipamorelin 5mg demonstrates a dual-receptor approach that yields greater GH release in vitro than either compound alone. Similarly, historical baselines are established by comparing CJC-1295 against early-generation analogs like sermorelin or ghrelin mimetics such as hexarelin. Assessing these compounds side by side clarifies differences in receptor desensitization, half-life, and biological potency across diverse growth hormone secretagogues.
Proper handling and reconstitution protocols are vital to preserving the structural integrity of CJC-1295 5mg lyophilized powder. The peptide is sensitive to mechanical agitation, temperature fluctuations, and pH extremes. Lyophilized vials should be stored at -20°C for long-term stability, protected from light exposure in desiccated storage containers.
Reconstitution should be conducted inside a laminar flow hood using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline, depending on the requirements of the assay. Diluent should be introduced slowly along the glass wall of the vial to prevent rapid turbulent dissolution, which can induce shear stress and cause peptide aggregation. Once reconstituted, the liquid solution must be kept refrigerated at 2°C to 8°C and utilized within an established testing window (typically 14 to 30 days depending on the solvent) to minimize hydrolytic degradation. For broader inventory requirements, institutions often manage stock through a dedicated wholesale account portal.
In laboratory research, compound purity directly influences experimental reproducibility. Low-purity peptide samples containing unreacted amino acids, truncated sequences, or residual organic solvents can produce confounding experimental artifacts. PX1 Research subjects every lot of CJC-1295 to rigorous analytical testing in an ISO 17025 accredited laboratory prior to release.
Purity is quantitatively verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity exceeding 99%. Identity is unequivocally confirmed through Electrospray Ionization Mass Spectrometry (ESI-MS), matching the observed molecular weight against theoretical values. Additionally, chromogenic Limulus Amebocyte Lysate (LAL) testing is performed to confirm that bacterial endotoxin levels remain strictly controlled below 0.5 EU/mg, protecting delicate cell cultures and animal models from endotoxin-induced inflammatory responses.
Securing consistent, high-grade reagents is essential for longitudinal preclinical research. PX1 Research operates fully compliant, state-of-the-art facilities located within the USA, eliminating international shipping delays and supply chain opacity. All synthesized compounds undergo rigorous lot-to-lot traceability from raw material synthesis to final lyophilization.
Laboratories sourcing compounds can review complete analytical documentation, including lot-specific Certificates of Analysis (COAs) containing raw HPLC chromatograms and mass spectra. Orders ship same-day from distribution centers in California and Arizona, providing researchers with fast, reliable access to our full catalog of high-purity research peptides.
What is CJC-1295 5mg used for in laboratory research?
CJC-1295 5mg is a synthetic GHRH analog used exclusively in preclinical research to examine growth hormone receptor binding, downstream IGF-1 gene expression, pituitary somatotroph signaling, and cellular repair pathways in vitro and in animal models.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that covalently binds to circulating albumin, significantly extending its biological half-life to several days. CJC-1295 without DAC (Modified GRF 1-29) lacks this complex, yielding a shorter half-life (approx. 30 minutes) that mimics acute physiological GHRH pulses.
How should CJC-1295 5mg be reconstituted for lab protocols?
CJC-1295 5mg should be reconstituted using sterile bacteriostatic water or sterile physiological saline inside a sterile environment. The diluent should be introduced down the side of the glass vial to prevent foaming or mechanical degradation of the peptide sequence.
What storage conditions maintain the stability of CJC-1295?
Lyophilized CJC-1295 powder should be stored long-term at -20°C in a dry, dark environment. Once reconstituted into liquid form, the solution must be stored at 2°C to 8°C and used within 14–30 days to avoid hydrolytic breakdown.
How does PX1 Research verify the purity of CJC-1295 5mg?
PX1 Research verifies every lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (≥99%) and Mass Spectrometry (MS) for structural identity. Endotoxin levels are quantified via LAL assay to guarantee levels below 0.5 EU/mg.
Can CJC-1295 be co-administered with ipamorelin in research assays?
Yes, in preclinical studies, GHRH analogs like CJC-1295 are frequently evaluated alongside GHRPs like Ipamorelin to investigate synergistic growth hormone release via dual receptor activation pathways.
Is CJC-1295 5mg approved for human therapeutic or medical use?
No. CJC-1295 5mg supplied by PX1 Research is strictly designated for laboratory research use only. It is not intended for human consumption, therapeutic use, or clinical administration under any circumstances.
Where does PX1 Research manufacture and ship CJC-1295?
PX1 Research manufactures peptides in USA-based, GMP-compliant facilities. Orders are fulfilled same-day (Monday–Friday) from regional distribution hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.